These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25631772)

  • 1. Minimal residual disease-directed therapy in acute myeloid leukemia.
    Kayser S; Schlenk RF; Grimwade D; Yosuico VE; Walter RB
    Blood; 2015 Apr; 125(15):2331-5. PubMed ID: 25631772
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia.
    Qin YZ; Jiang Q; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ
    Blood Cancer J; 2021 Apr; 11(4):67. PubMed ID: 33795645
    [No Abstract]   [Full Text] [Related]  

  • 3. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
    Yalniz FF; Patel KP; Bashir Q; Marin D; Ahmed S; Alousi AM; Chen J; Ciurea SO; Rezvani K; Popat UR; Shpall EJ; Champlin RE; Oran B
    Cancer; 2020 May; 126(10):2183-2192. PubMed ID: 32101640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1.
    Wei H; Liu X; Wang Y; Lin D; Zhou C; Liu B; Qiu S; Gu R; Li Y; Wei S; Gong B; Liu K; Gong X; Liu Y; Zhang G; Fang Q; Zhang J; Jin J; Ma Y; Mi Y; Wang J
    Exp Hematol; 2021 Apr; 96():63-72.e3. PubMed ID: 33524443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
    Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ
    J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
    Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
    Narimatsu H; Iino M; Ichihashi T; Yokozawa T; Hayakawa M; Kiyoi H; Takeo T; Sawamoto A; Iida H; Tsuzuki M; Yanada M; Naoe T; Suzuki R; Sugiura I
    Int J Hematol; 2008 Sep; 88(2):154-158. PubMed ID: 18553224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.
    Pigazzi M; Manara E; Buldini B; Beqiri V; Bisio V; Tregnago C; Rondelli R; Masetti R; Putti MC; Fagioli F; Rizzari C; Pession A; Locatelli F; Basso G
    Haematologica; 2015 Mar; 100(3):e99-101. PubMed ID: 25480496
    [No Abstract]   [Full Text] [Related]  

  • 10. Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML.
    Cook JA; Lott L; Perry J; Eckel AM; Xu D; Hudson CA; Wells DA; Loken MR; Menssen AJ
    Blood; 2024 Aug; 144(5):581-585. PubMed ID: 38749014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapsed RUNX1-RUNX1T1-positive acute myeloid leukemia with pseudo-Chediak-Higashi granules.
    Kondo H; Kanayama T; Matsumura U; Urata T; Osone S; Imamura T; Inaba T; Hosoi H
    Int J Hematol; 2021 May; 113(5):616-617. PubMed ID: 33782817
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapy-related acute myeloid leukemia with inv(16) after successful therapy for de novo acute myeloid leukemia with t(8;21).
    Shao H; Yang Q; Wu C; Cen J; Chen S; Pan J
    Ann Hematol; 2017 Dec; 96(12):2127-2129. PubMed ID: 28840298
    [No Abstract]   [Full Text] [Related]  

  • 13. Monitoring of minimal residual disease in acute myeloid leukemia with t(8;21)(q22;q22).
    Zhang L; Li Q; Li W; Liu B; Wang Y; Lin D; Zhou C; Li C; Wang J; Mi Y
    Int J Hematol; 2013 Jun; 97(6):786-92. PubMed ID: 23613269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitation of minimal residual disease in t(8;21)-positive acute myelogenous leukemia patients using real-time quantitative RT-PCR.
    Sugimoto T; Das H; Imoto S; Murayama T; Gomyo H; Chakraborty S; Taniguchi R; Isobe T; Nakagawa T; Nishimura R; Koizumi T
    Am J Hematol; 2000 Jun; 64(2):101-6. PubMed ID: 10814988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients.
    Höllein A; Jeromin S; Meggendorfer M; Fasan A; Nadarajah N; Kern W; Haferlach C; Haferlach T
    Leukemia; 2018 Oct; 32(10):2270-2274. PubMed ID: 29568097
    [No Abstract]   [Full Text] [Related]  

  • 16. [Two cases of systemic mastocytosis with RUNX1-RUNX1T1 positive acute myeloid leukemia treated with sequential avapritinib after allogeneic hematopoietic stem cell transplantation and literature review].
    Wang J; Zu YL; Gui RR; Li Z; Zhang Y; Zhou J
    Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):505-508. PubMed ID: 38964927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia.
    Lee JW; Kim S; Jang PS; Chung NG; Cho B; Im SA; Kim M
    J Pediatr Hematol Oncol; 2020 Apr; 42(3):e132-e139. PubMed ID: 31688618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations.
    Delsing Malmberg E; Rehammar A; Pereira MB; Abrahamsson J; Samuelsson T; Ståhlman S; Asp J; Tierens A; Palmqvist L; Kristiansson E; Fogelstrand L
    J Mol Diagn; 2019 Jan; 21(1):149-162. PubMed ID: 30273780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
    Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
    Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute myeloid leukemia (aml) subtype M2 with variation of the t (8;21)translocation and AML1/ETO expression].
    Llimpe Y; Monteza R; Ticlahuanca J; Rubio P; Ortíz C; Arias A
    Rev Peru Med Exp Salud Publica; 2013 Mar; 30(1):145-6. PubMed ID: 23612831
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.